Drug Profile
Research programme: inhaled cystic fibrosis therapeutics - Vectura/Chiesi
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Activaero GmbH; Chiesi Farmaceutici
- Developer Chiesi Farmaceutici; Vectura
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in Italy (Inhalation)
- 13 Mar 2014 Activaero GmbH has been acquired by Vectura
- 09 Sep 2013 Preclinical trials in Cystic fibrosis in Italy (Inhalation)